Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: Parallel topotecan escalation in two fixed platinum dosing schemes

Chemotherapy

Volumn 51, Issue 2-3, 2005, Pages 154-161

  Pentheroudakis, G ^a   Briasoulis, E ^a   Karavassilis, V ^a   Mauri, D ^a   Tzamakou, E ^a   Rammou, D ^a   Pavlidis, N ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cisplatin; Combination chemotherapy; Phase I trial; Topotecan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; RECOMBINANT ERYTHROPOIETIN; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPOMAGNESEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; TOPOTECAN;

EID: 22144484525     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085624     Document Type: Article

References (15)

1. Sorrenson C, Eastman A: Mechanism of cis-diamminedichloroplatinum II-induced cytotoxicity: Role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-4488.
2. Mese H, Ueyama Y, Suzuki A, Nakayama S, Sasaki A, Hamakawa H, Matsumura T: Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line. Chemotherapy 2001;47:136-142.
3. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49:5077-5082.
4. Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 1998;16:2233-2237.
5. De Jonge MJA, Sparreboom A, Verweij J: The development of combination therapy involving camptothecins: A review of preclinical and early clinical studies. Cancer Treat Rev 1998; 24:205-220.
6. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter J, Schellens JH: Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998;41:307-316.
7. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC: Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996;14:3074-3084.
8. Rowinsky EK, Kaufmann SH: Topotecan in combination chemotherapy. Semin Oncol 1997;S20-11-S20-26.
9. Nakanishi Y, Takayama K, Wataya H, Izumi M, Minami T, Takano K, Inoue K, Osaki S, Kimotsuki K, Harada T, Hara N: Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumours. Chemotherapy 2002;48:205-210.
10. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M, Saijo N: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 1996;56:789-793.
11. Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, Ten Velde G, Bosquee L, Legrand C, Neumaier C, King K: EORTC 08957 phase II study of topotecan in combination with cisplatin as second line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003;9:143-150.
12. De Jonge M, Loos WJ, Gelderblom H, Planting A, van der Burg M, Sparreboom A, Brouwer E, van Beurden V, Mantel M, Doyle E, Hearn S, Ross G, Verweij J: Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects. J Clin Oncol 2000;18:2104-2115.
13. Sorensen M, Jensen PB, Herrstedt J, Hirsch FR, Hansen HH: A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small cell lung cancer. Ann Oncol 2000;11:829-835.
14. Rowinsky EK: Weekly topotecan: An alternative to topotecan's standard daily x 5 schedule? Oncologist 2002;7:324-330.
15. Von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Riviere A, Camlett I, Lane S, Ross G: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small cell lung cancer. J Clin Oncol 2001;19:1743-1749.